Teva Pharmaceutical Industries. Information about the issuer. (LEI 549300BAFGM4RC74ZJ94, SWIFT TEVPILITXXX). News and credit ratings. Tables with accounting and financial reports.
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024 | Business Wire
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
Teva Pharmaceuticals has acquired success with Actavis Generics | World Finance
Teva Executive Calls Company's Fourth Quarter “Fairly Good” | Ctech
Teva pharmaceutical industries - Pharma
Credit Trends: Potential Downgrades Reach Another Record High Amid COVID-19 Stress | S&P Global Ratings
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Credit Rating Process | A Complete Beginner's Guide
Teva Pharmaceutical (TEVA)
.png?upscale=true&width=1400&upscale=true&name=US%20Benchmark%20%26%20Global%20Indices%204%20Sep%20(1).png "Chinese Developers Face Liquidity Test; Teva, Nordstrom, Sappi Downgraded; Macy's Q2 Earnings Beat Estimates - Track Live Bond Prices Online with BondEValue App -")
Chinese Developers Face Liquidity Test; Teva, Nordstrom, Sappi Downgraded; Macy's Q2 Earnings Beat Estimates - Track Live Bond Prices Online with BondEValue App -
The Possible Reason why Teva (NYSE:TEVA) is Still Trading Below Intrinsic Value - Simply Wall St News
Fitch downgrades Teva debt - Globes
S&P downgrades Teva, pushing credit rating further into junk territory - Business - Haaretz.com
CSRWire - Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva eases debt burden with $400M tender offer as turnaround effort escalates | Fierce Pharma
Teva Bonds: 8.8% Yield To Maturity Understates Upside (NYSE:TEVA) | Seeking Alpha
Credit Rating Process | A Complete Beginner's Guide
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
S&P cuts Teva's rating on rising litigation risks
Teva Bonds: 8.8% Yield To Maturity Understates Upside (NYSE:TEVA) | Seeking Alpha
Teva Bonds: 8.8% Yield To Maturity Understates Upside (NYSE:TEVA) | Seeking Alpha
S&P: Teva faces greatest liability in US antitrust suit - Globes
